# A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)

> **NCT05130450** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 60 (actual)

## Conditions studied

- Familial Chylomicronemia Syndrome

## Interventions

- **DRUG:** Olezarsen

## Key facts

- **NCT ID:** NCT05130450
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-11-18
- **Primary completion:** 2028-02
- **Final completion:** 2028-02
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05130450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05130450, "A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT05130450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*